Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Richtig, G; Cerroni, L; Schmidt, H; Beham-Schmid, C; Deinlein, T; Vallant, C; Richtig, E.
Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions - a case series.
J Eur Acad Dermatol Venereol. 2021; 35(3):e209-e211
Doi: 10.1111/jdv.16922
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Richtig Georg
- Co-authors Med Uni Graz
- Beham-Schmid Christine
- Cerroni Lorenzo
- Kränke Teresa Maria
- Richtig Erika
- Schmidt Helmut
- Vallant Christina Martha
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Talimogene laherparepvec (T-VEC) is a genetically engineered herpes simplex virus type 1 (HSV-1) and used in locally advanced melanoma patients. Its mode of action is not fully understood. We present three cases where T-VEC caused monoclonal as well as polyclonal B-cell infiltration. This article is protected by copyright. All rights reserved.